MedPath

Effects of Diet and Exercise on Circadian Glycemia

Not Applicable
Completed
Conditions
Glucose Intolerance
Registration Number
NCT03922685
Lead Sponsor
University of Michigan
Brief Summary

Specific aims of the study are:

1. to evaluate whether a 24-h exposure to a 25%-carbohydrate diet will reduce postprandial glycemia to the same extent in the evening (19 h) as in the morning (7 h),. and

2. to determine whether one hour of post-meal moderate intensity exercise (at 50% of maximal effort) will further reduce postprandial glycemia.

The outcome measures are: plasma concentrations of glucose, insulin, glucose-dependent-insulinotropic peptide (GIP), leptin, and the ketone body beta-hydroxybutyrate.

Detailed Description

The two hypotheses in this study are:

1. A 24-h exposure to a 25%-carbohydrate diet will reduce postprandial glycemia to the same extent in the evening (19 h) as in the morning (7 h), and

2. One hour of moderate-intensity exercise (at 50% of maximal effort) will further reduce postprandial glycemia to the same extent in the evening (19 h) as in the morning (7 h).

Eight postmenopausal subjects (age 58.5 years, BMI 25.6 kg/m2) participated in 4 24-h long crossover trials, two terminating at 7h and the other 2 at 19h. At each circadian time one trial required 60 minutes of moderate-intensity exercise (50% of maximal effort), and the other two involved no exercise.

Three 25%-carbohydrate meals prepared by the Michigan Clinical Research Unit (MCRU) kitchen, were eaten at subjects' home, and the fourth was eaten 20 minutes after subjects' arrival at MCRU at either 19 h or 7 h. Blood was collected from antecubital catheter at 10-minute intervals until 23:20 h or 11:20 h, respectively.Plasma was treated with protease inhibitor to preserve GIP, frozen at -80o C until glucose measurements by glucose oxidase, hormone measurements by chemiluminescence, and ketone measurements by Abbott meter strips.

Exercise intensity was determined before the exercise trials on a treadmill from oxygen consumption (VO2) and carbon dioxide production (VCO2) by subjects walking on a treadmill at 3 mph with the treadmill slope increased by 2% every 3 minutes. Maximal effort was established when respiratory exchange ratio (VCO2/VO2) reached or exceeded 1. The treadmill speed and slope at half maximal effort was used during the one-hour exercise bout which was initiated 40 minutes after the start of the meal.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
8
Inclusion Criteria
  • postmenopausal
  • normal blood glucose
  • no cholesterol medication
  • age between 50 an 65 years
  • overweight but not obese
  • BMI between 25 and 30 kg/m2
  • weight-stable during past 6 months
  • exercise less than 20 minutes three times a week
Exclusion Criteria
  • metabolic disease other than hormonally-corrected hypothyroidism
  • musculo-skeletal disability that would preclude exercise
  • smoker
  • do not meet inclusion criteria

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
Postprandial glucose concentrationFour hours: 19:20 to 23:20 in the evening trials; 7:20 to 11:20 in the morning trials

The area under the postprandial glucose curve

Postprandial insulin concentrationFour hours: 19:20 to 23:20 in the evening trials; 7:20 to 11:20 in the morning trials

The area under the postprandial insulin curve

Secondary Outcome Measures
NameTimeMethod
Postprandial leptin concentrationFour hours: 19:20 to 23:20 in the evening trials; 7:20 to 11:20 in the morning trials

The area under the leptin postprandial curve

Postprandial glucose-dependent insulinotropic peptide (GIP) concentrationFour hours: 19:20 to 23:20 in the evening trials; 7:20 to 11:20 in the morning trials

The area under the postprandial GIP curve

Postprandial beta-hydroxybutyrate concentrationFour hours: 19:20 to 23:20 in the evening trials; 7:20 to 11:20 in the morning trials

The area under the beta-hydroxybutyrate postprandial curve

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.